CAR T cells could be repurposed to target senescent cells and delay the effect of aging. A study by scientists at Cold Spring Harbor Laboratory showed how to design them and demonstrated the advantages of this therapy in mice. “We only gave one dose, and we could have benefits [for] really long periods of time,” lead author Corina Amor told BioWorld.
Applying chimeric antigen receptor (CAR) T-cell therapy to T-cell malignancies presents important limitations due to immune suppression caused by T-cell depletion, in addition to CAR T self-killing and CAR T transfection of malignant cells.
Tr1x Inc. announced a $75 million series A financing to advance universal allogeneic regulatory T (Treg) and chimeric antigen receptor (CAR)-Treg cell therapies into the clinic to treat autoimmune and inflammatory diseases.
Sana Biotechnology Inc. has obtained FDA clearance of its IND application to conduct a study of SC-262 in patients with relapsed or refractory B-cell malignancies, initially in patients who have received prior CD19-directed chimeric antigen receptor (CAR) T therapy.
Abbvie Inc. and Umoja Biopharma Inc. have announced two exclusive option and license agreements to develop multiple in situ generated chimeric antigen receptor (CAR)-T cell therapy candidates in oncology using Umoja's proprietary Vivovec platform.
Iaso Biotherapeutics Co. Ltd. has established new collaborations with Umoja Biopharma Inc. for the development and commercialization of novel ex vivo and in vivo cell and gene therapies. These collaborations seek to advance off-the-shelf cell and gene therapies with applications in oncology and immunology.
Chimeric antigen receptor (CAR) therapies targeted against CD19 have been widely used for the treatment of B-cell malignancies. However, the down-regulation of CD19 can lead to relapse, and autologous CAR T therapies have limitations that need to be addressed.
It is known that CD19-directed CAR T-cell therapy is useful in the treatment of large B-cell lymphoma, but about 60% of patients relapse after treatment, and about 30% of these are CD19-negative patients with poor survival. Sana Biotechnology Inc. is developing a hypoimmune CD22-directed CAR T-cell therapy, named SC-262, for the potential treatment of large B-cell lymphoma.
Vittoria Biotherapeutics Inc. has received FDA clearance of its IND application to initiate a first-in-human phase I trial with VIPER-101, a gene-edited, autologous, chimeric antigen receptor (CAR) T-cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma.
Chimeric Therapeutics Ltd. has received FDA clearance of its IND application for CHM-2101, a first-in-class CDH17 chimeric antigen receptor (CAR) T cell therapy for gastrointestinal (GI) cancers.
RSS
